Benefits
Urinary tract health
Cranberry has been widely studied for urinary tract health. A 2026 overview of systematic reviews found cranberry to be one of the non-antibiotic options supported by systematic reviews, in women aged 16 or over who already have recurrent urinary tract infections, defined as 2 or more in 6 months or 3 or more in 12 months. The same authors say questions remain around dose, duration and adherence. That work looked at cranberry as a category, not at this product.
Anti-adhesion action
In laboratory work, cranberry proanthocyanidins reduce the ability of certain E. coli to stick to cells of the urinary lining. This is the leading proposed mechanism rather than a proven one, and nothing cited on this page tested whether this product does it in people.
Polyphenol content, no antioxidant outcome tested
Cranberry is rich in polyphenols, which show antioxidant activity in laboratory tests. Nothing cited on this page measured an antioxidant outcome, for this product or for cranberry generally, so this is background about the fruit rather than a tested effect.
Mechanism of action
Type-A proanthocyanidins
Cranberry's distinctive type-A PACs interfere with the fimbriae E. coli use to adhere to the urinary lining, so fewer bacteria attach. This is laboratory work. Type-A PAC content also varies widely between cranberry products, so a milligram figure for concentrate does not tell you how much PAC you are getting.
Polyphenol antioxidants
Cranberry's polyphenols show antioxidant activity in laboratory tests. No human antioxidant measurement is cited here, so this is chemistry rather than a demonstrated health effect.
Clinical trials
Overview of systematic reviews of randomised controlled trials of community-based non-antibiotic ways to prevent repeat urinary tract infections in women. The authors searched MEDLINE, EMBASE, CINAHL, Google Scholar and Cochrane from January 2014 to May 2025 and included 27 systematic reviews, 6 of them on cranberry. No cranberry product or PAC amount is named in the abstract, and the authors say questions remain around dose and duration. (Santer et al. 2026, British Journal of General Practice)
Women aged 16 or over with recurrent urinary tract infections, defined as 2 or more in 6 months or 3 or more in 12 months. Studies in intensive care units and in people with indwelling catheters were excluded. This is a clinical population under medical care, not the general public.
The authors report that cranberry and methenamine hippurate use are supported by systematic reviews, as is vaginal oestrogen among postmenopausal women, although questions remain around dose, duration and treatment adherence. Their overall conclusion is that questions remain about optimal use and that for many interventions stronger evidence is needed. Cranbey itself was not studied.